The correlation between IGF-1R and HER-2 expression with mitosis count and histopathological grade in invasive breast carcinoma of no special type

Authors

  • Yessy Setiawati
  • Aswiyanti Asri
  • Rosfita Rasyid

DOI:

https://doi.org/10.55816/mpi.v29i3.442

Keywords:

: Invasive breast carcinoma of NST, IGF-1R, HER-2.

Abstract

Background
The IGF-1R signaling pathways have cross-talk with HER-2 signaling pathways and was thought to be one of the resistance mechanism in
trastuzumab therapy. This research was proposed to analyze the correlation between IGF-1R and HER-2 expression with mitosis count and
histopathological grade in invasive breast carcinoma of no special type.
Methods
This research was a cross-sectional design. A total of fifty-five invasive breast carcinoma of no special type cases diagnosed in the
Anatomical Pathology Centre Diagnostic of Medical Faculty of Andalas University in a period of 2014-2015 were collected and stained
immunohistochemically with IGF-1R and HER-2 antibodies. IGF-1R and HER-2 expression were examined and their correlation with mitosis
count and histopathological grade were statistically analyzed with T-test, Oneway Anova and Chi-Square test.
Results
IGF-1R cytoplasm and membranous expression were found positive in 18.2% and 34.5% cases respectively, meanwhile, HER-2 expressions
were found positive in 23.6% cases of invasive breast carcinoma of no special type. There were significant correlations between IGF-1R
cytoplasm expression with mitosis count (p=0.049). There were no significant correlations between IGF-1R membranous expression with
mitosis count (p=0.641) with histopathological grade (p=1.00). There were no significant correlations between HER-2 expression with
mitosis count (p=0,495) and histopathological grade (p=1.000).
Conclusion
IGF-1R expressions have a significant correlation with mitosis count rather than HER-2 expressions. Inhibition it’s signaling pathways may
have therapeutic value in breast carcinoma. Combination therapy of anti-HER-2 and anti-IGF-1R are expected to overcome resistance with
trastuzumab in HER-2 positive breast carcinoma

Downloads

Download data is not yet available.

Downloads

Published

2020-09-07

Issue

Section

Articles